Effective treatment of
allergic asthma and eczema
– without side effects

Airsonett® Air4 is a medical device for effective home treatment of allergic asthma and eczema. The patented TLA technology provides 99.5% clean air in the breathing zone. Your airways and immune system can rest and recuperate when you sleep, and you wake up rested, ready for a new day.

Effective

> Reducing exacerbations1
> Improved control of allergic diseases 1, 2, 3, 4
> Improved quality of life 2, 3
> No pharmacological side effects 2

Clinically proven

Airsonett Air4 is proven to reduce exacerbations and to reduce inflammation in the airways. The clinical effects are seen after 3 months (sleep improves in 1 month).

Economical

Health economics studies confirm lower treatment costs compared to pharmacological treatment options, fewer clinic visits and better control over patient symptoms.

item03_grey
Safe Non-invasive treatment without pharmacological side effects
item04_grey
Trusted Registered medical device as proof of reliability and quality
item01_grey
Easy to use A home treatment device, designed to be easy to install and use
nothing but clean air

This is how simple it is

Illustration - allergen exposure
Allergen exposure is high during sleep
Illustration - clean air
Airsonett® Air4 provides 99.5% clean air in the breathing zone
Illustration - sleeping
Your body has the opportunity to rest and recharge

Why Air4? It’s effective

Man in blue shirt

 

Dr. Robert Boyle et al

Published in Thorax (2012)

”…we have demonstrated that nocturnal control of aeroallergen exposure…can improve quality of life and reduce airway inflammation in adults and children with atopic asthma, without significant adverse effects.”

Airsonett_model_blue_back@1x
Interested in Air4?

Air4 is available either to rent or to purchase.

If you have a patient who would benefit from using Air4, please contact us here.

Contact us

News

Read the latest news on Airsonett and see where you can meet us at tradeshows or demo events.

The Swedish national healthcare region of Östergötland signs central agreement with Airsonett for treatment with TLA for patients with severe allergic asthma
July 8, 2019

The expert group for respiratory organs in the region of Östergötland has since 2016 recommended TLA as a complementary treatment for adults and children over 6 with severe asthma, who, despite optimal medication, have uncontrolled asthma. However, the prescription was previously limited to the allergy center in Linköping. With the new central agreement, it is possible to prescribe TLA in the whole healthcare region of Östergötland, which will attribute to fair and even care throughout the entire region.

“The agreement with the region of Östergötland is further proof of the increased acceptance of the treatment with Airsonett TLA in healthcare in Sweden. We expect that 2-3 larger regions in Sweden will sign similar agreements with us during autumn”, says Anders Due-Boje, CEO Airsonett AB.

 

About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed, and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.

 

For more information:
Anders Due-Boje, CEO, Airsonett AB
Phone: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

 

About Airsonett
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett® Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett® Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep. Airsonett® Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett® Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu

Airsonett supports the Allergy Diary App – assists in the care of allergic asthma
March 1, 2019

The new app Allergy Diary has been developed for IOS and Android in collaboration between MACVIA-LR and ARIAR, a European network for monitoring allergy. The app is an important tool for the effective treatment of severe allergic asthma as it assists patients in keeping track of their symptoms. The app is simple to use, and combines practicality with good scientific practice, having been developed with a global team of world leading allergy clinicians. The app can be downloaded here (https://itunes.apple.com/fi/app/allergy-diary-by-macvia-aria/id983596216?mt=8, https://play.google.com/store/apps/details?id=nl.peercode.allergydiary&hl=en ) and on Airsonett’s website.

“In order for the healthcare system to be able to follow the daily changes, the importance of some form of symptom diary is great” says Therese Sterner, Leg. Allergy, Asthma and COPD nurse with skin specialization. She continues: “This can easily be done through the Allergy Diary app. Studies have shown positive results with this form of allergy diary, as it monitors symptom changes over time which assists both the user and the health care system,”.

Anders Due-Boje, CEO of Airsonett, agrees: “In all treatment it is of the utmost importance that patients can document their symptoms. We support this app to help patients easily keep track of their symptoms so the national health services can provide optimal care for each patient. ”

Airsonett is a unique treatment for allergic asthma
Airsonett® Air4 is a medical device for effective home treatment of allergic asthma and eczema. The patented TLA technology provides 99.5% clean air in the breathing zone. Your airways and immune system can rest and recuperate when you sleep, and you wake up rested, ready for a new day. The technology is clinically documented for several years and now wins land in many county councils.

“As my role as an Allergy Nurse, both in the County Council and as a consultant, I monitor children and adults since 2007 with severe asthma who have an Airsonett installed. Sleeping under an Airsonett has, with a few exceptions, resulted in huge improvements for the individual patient but also for the family. Sleeping undisturbed without coughing and itching a whole night increases the possibility of a better everyday life”, says Therese Sterner, Leg. Allergy, Asthma and COPD nurse with skin specialization.

Download the Press release as pdf.

For more information:
Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

Airsonett’s TLA technology is now included in the guidelines for treatment of severe asthma in the South Swedish national health care
January 22, 2019

National health care in the South Swedish region of Skåne has updated its guidelines for treatment of patients with severe allergic asthma. Airsonett and the treatment with the TLA technology (Temperature-controlled Laminar Airflow)has been given its own guidelines based on the primary indication to prevent asthma attacks (exacerbations). The guidelines have been established by the Director of Health Care in Region Skåne.

Treatment with Airsonett TLA can be prescribed in Region Skåne by doctors specializing in allergy-, lung-, or child medicine and experience of treatment of severe asthma.

For complete guidelines of Airsonett TLA, Region Skåne:

https://vardgivare.skane.se/vardriktlinjer/medicinska-omraden/allergi/#30699

”Airsonett and treatment with TLA have been included in the national guidelines for asthma treatment since 2015. The fact that Region Skåne now introduces its own guidelines for Airsonett TLA is further proof of the positive effect the treatment has on patients with severe allergic asthma”, says Anders Due-Boje, CEO Airsonett AB.

 

About severe, uncontrolled asthma

Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed,and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.

Download the press release as pdf.

For more information:

Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu

News